Non-Infectious Active Uveitis
Conditions
Keywords
Non infectious active uveitis, Soluble-CD95-Ligand
Brief summary
The study aims at defining the role of soluble CD95 Ligand in the physiopathology of the non-infectious uveitis. Soluble CD95 Ligand might have a prognostic interest as well as potential for the discovery of new therapeutic strategies
Detailed description
Non-Infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. Actually, the knowledge of the physiopathology of uveitis stay poorly. CD95 Ligand (CD95-L) belongs to a TNF (tumor necrosis factors) receptor family. It knows to play a preponderant role to maintain the eye immune privilege. In particular conditions depending on immunologic environment, CD95-L has pro-inflammatory properties and can interact with Th17 lymphocytes and neutrophils, two cells implicated in non-infectious uveitis. The hypothesis is that s-CD95-L levels might be a prognostic factor in non-infectious uveitis and the study of the molecular mechanisms involved could provide new therapeutic targets. This study will recruit 100 patients with non-infectious uveitis followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected during to assess s-CD95-L. Fundamental research will be realized on patients' sample to evaluate underlying molecular mechanisms. Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, accordingly to usual care.
Interventions
OTHERs-CD95-L
levels of s-CD95-L (ELISA test)
Sponsors
University Hospital, Bordeaux
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Diagnosis of non-infectious uveitis according to the SUN (Standardization of the Uveitis Nomenclature) working Group; * Age ≥ 18 years; * being affiliated to health insurance, * willing to participate.
Exclusion criteria
* Pregnant or breastfeeding women, * patient under legal protection measure , * poor understanding of the French language
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| levels of s-CD95-L | Baseline | levels of s-CD95-L (ELISA test) in sera of non-infectious uveitis patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between levels of s-CD95-L and Disease activity score | Baseline, Month 3 | Correlation between levels of s-CD95-L and Disease activity score (as defined by ophthalmologic examination) |
| Th17 dosage | Baseline, Month 3 | Th17 dosage |
| polynuclear neutrophils levels | Baseline, Month 3 | polynuclear neutrophils levels (Flow cytometry) |
Countries
France
Outcome results
None listed